Consult the medical resource doctors trust

UpToDate is one of the most respected medical information resources in the world, used by over 360,000 doctors and thousands of patients to find answers to medical questions.

  • Content written by a faculty of over 4,000 physicians from leading medical institutions
  • Unbiased: free of advertising or pharmaceutical funding
  • Evidence-based treatment recommendations
  • Continuously updated to incorporate new medical findings

Excitation-contraction coupling in myocardium

INTRODUCTION

Excitation-contraction (E-C) coupling refers to the series of events that links the action potential (excitation) of the muscle cell membrane (the sarcolemma) to muscular contraction. Although E-C coupling in myocardium is similar in many ways to skeletal muscle and smooth muscle, there are also critical differences. The cyclical nature of cardiac contraction and the importance of myocardial relaxation to cardiac pump function requires that any discussion of E-C coupling also consider the events terminating the muscle twitch as an integral part of the subject. Modulation of muscular function is said to affect inotropy (the speed and strength of muscular contraction) or lusitropy (the ability of the muscle to relax). Increased knowledge about E-C coupling has been a key to understanding both the inotropic and lusitropic states, and it continues to be useful in developing improved therapy for congestive heart failure and cardiogenic shock.

This is a brief review of cardiac excitation (the myocardial action potential) followed by a description of muscular contraction. E-C coupling is then presented as the transduction of a membrane signal (the action potential) to an intracellular effector (the contractile apparatus) by way of a second messenger (intracellular free calcium [Ca2+]).

MYOCARDIAL ACTION POTENTIAL

The resting membrane potential of the myocardial cell is cell interior negative (-90 mV), and is primarily determined by the ratio of intracellular-to-extracellular potassium as predicted by the Nernst equation. The action potential is a temporary depolarization of the membrane. It is caused by transient changes in membrane conductance of several charged ions, especially sodium, due to the opening and closing of ion-specific channels in the membrane. This process can be summarized as follows (graph 1 and movie 1) [1]. (See "Myocardial action potential and action of antiarrhythmic drugs".)

  • Rapid depolarization (phase 0) occurs when the resting cell is brought to threshold, leading sequentially to activation or opening of voltage-dependent sodium channels, rapid sodium entry into the cells down a favorable concentration gradient, and a cell interior positive potential that can approach +45 mV. The marked depolarization results in voltage-dependent inactivation of the sodium channels and cessation of the inward sodium flux. Calcium channels also open during depolarization but the onset of the inward calcium flux is much slower.
  • Phase 1 repolarization is primarily due to inactivation of the sodium channels with abolition of the inward sodium current.
  • This is followed by a plateau in phase 2 in which continued slow calcium entry into the cell balances the electrical effect of potassium loss, as more voltage-dependent potassium channels open up. The voltage in the plateau phase is sufficient to maintain the sodium channels in the closed, inactive state.
  • The cessation of the calcium current and a further increase in potassium current leads to rapid completion of repolarization with return to the resting potential (phase 3).
  • Normal cell sodium and potassium activities are restored by the Na-K-ATPase pump, which extrudes the sodium that entered during depolarization and pumps in the potassium that was lost during repolarization.

The action potential at a specific region of membrane is conducted along the membrane and depolarizes neighboring regions, causing their thresholds to be reached, thereby generating another local action potential. This process conducts the action potential as an electrical signal along the muscle fibers of the heart. Linear propagation of the action potential occurs rapidly because the myocytes along muscle fibers are electrically continuous. An action potential can also cause the depolarization of a neighboring fiber, and the electrical impulse occurs as a "wave" through the heart.

To continue reading this article you need to subscribe.

Read the rest of this article and others like it

The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2010 UpToDate, Inc.
References Top
  1. Katz, AM. Mechanism and control of the cardiac contractile process. Physiology of the Heart, Raven Press, New York 1992. p.178.
  2. Smith, TW. Digitalis: Mechanisms of action and clinical use. N Engl J Med 1988; 318:358.
  3. Katz, AM. Cyclic adenosine monophosphate effects on the myocardium: A man who blows hot and cold with one breath. J Am Coll Cardiol 1983; 2:143.
  4. Frank, K, Kranias, EG. Phospholamban and cardiac contractility. Ann Med 2000; 32:572.
  5. Scholz, J, et al. Alpha-1 adrenoceptor-mediated positive inotropic effect and inositol trisphosphate increase in mammalian heart. J Pharmacol Exp Ther 1988; 245:327.
  6. Baker, KM, Booz, GW, Dostal, DE. Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992; 54:227.
  7. Dzau, VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153:937.
  8. Sadoshima, J, Xu, Y, Slayter, HS, Izumo, S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac muscle in vitro. Cell 1993; 75:977.
  9. Holubarsch, C, Hasenfus, G, Schmidt-Schweda, S, et al. Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium: An in vitro study under physiologic conditions. Circulation 1993; 88:1228.
  10. Kaumann, A, Bartel, S, Molenaar, P, et al. Activation of ß2-adrenergic receptors hasten relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 1999; 99:65.
  11. Hoh, JF, Rossmanith, GH, Kwan, LJ, Hamilton, AM. Adrenaline increases the rate of cycling of crossbridges in rat cardiac muscle as measured by pseudo-random binary noise-modulated perturbation analysis. Circ Res 1988; 62:452.
  12. Puceat, M, Clement, O, Lechene, P, et al. Neurohumoral control of calcium sensitivity of myofilaments in rat single heart cells. Circ Res 1990; 67:517.
  13. Orchard, CH, Kentish, JC. Effects of pH on the contractile function of cardiac muscle. Am J Physiol 1990; 258:C967.
  14. Poole-Wilson, PA. Regulation of intracellular pH in the myocardium; relevance to pathology. Mol Cell Biochem 1989; 89:151.
  15. Solaro, JR, Saleh, SC, Kentish, JC. Ca2+, pH and the regulation cardiac myofilament force and ATPase activity. Mol Cell Biochem 1989; 89:163.
  16. Gomez, AM, Guatimosim, S, Dilly, KW, et al. Heart failure after myocardial infarction: altered excitation-contraction coupling. Circulation 2001; 104:688.
  17. Gwathmey, JK, Copelas, L, MacKinnon, R, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987; 61:70.
  18. Hobai, IA, O'Rourke, B. Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contraction coupling in canine heart failure. Circulation 2001; 103:1577.
  19. Morgan, JP. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N Engl J Med 1991; 325:625.
  20. Grossman, W. Diastolic dysfunction in congestive heart failure. N Engl J Med 1991; 325:1557.
  21. Soufer, R, Wohlengaster, D, Vita, NA, et al. Intact systolic left ventricular function in clinical congestive heart failure. Am J Cardiol 1985; 55:1032.
  22. Feldman, MD, Copelas, L, Gwathmey, JK, et al. Deficient production of cyclic AMP: Pharmacolgical evidence of an important cause of contractile dysfunction in end-stage heart failure. Circ 1987; 75:331.
  23. Nabauer, M, Bohm, M, Brown, L, et al. Positive inotropic effects in isolated ventricular myocardium from failing and non-failing human hearts. Eur J Clin Invest 1988; 18:600.
  24. Packer, M, Carver, JR, Rodeheffer, RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325:1468.
  25. Kubo, SH, Gollub, S, Bourge, R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. Circulation 1992; 85:942.
white circle LOG IN
white circle DEMO